Cytokine Storm Implicates Use of Baricitinib in Hospitalized amCOVID-19 Patients
Time: 11:55 am
day: Day One
Details:
- Narrating Lilly’s fast- approval process for Baracitinib for pandemic application
- Addressing the MOA of a cytokine storm and effects this provides on JAKi use
- Potential anti-host anti-viral mechanism for Baricitinib and potential implications
